Autoimmune Thyroid Diseases in Patients Treated with Alemtuzumab for Multiple Sclerosis: An Example of Selective Anti-TSH-Receptor Immune Response

Induction of New Autoimmune Diseases After Alemtuzumab Therapy for Multiple Sclerosis

(2017) Lawrence Steinman   JAMA Neurology

Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab

(2017) David Baker et al.   JAMA Neurology

Therapeutic strategies targeting B-cells in multiple sclerosis

(2016) Ron Milo   AUTOIMMUNITY REVIEWS

Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis

(2016) Mark Obermann et al.   Multiple Sclerosis Journal

Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis

(2016) Mark Obermann et al.   Multiple Sclerosis Journal

Management of hyperthyroidism due to Graves’ disease: frequently asked questions and answers (if any)

(2016) L. Bartalena et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

Thyrotropin Receptor Epitope and Human Leukocyte Antigen in Graves’ Disease

(2016) Hidefumi Inaba et al.   Frontiers in Endocrinology

Alemtuzumab Induced Thyroid Disease in Multiple Sclerosis: A Review and Approach to Management

(2015) Moeber Mahzari et al.   CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

Graves’ Disease Mechanisms: The Role of Stimulating, Blocking, and Cleavage Region TSH Receptor Antibodies

(2015) S. Morshed et al.   HORMONE AND METABOLIC RESEARCH

Etiopathogenesis of Basedow’s disease

(2015) P. Leporati et al.   NUKLEARMEDIZIN-NUCLEAR MEDICINE

Graves' disease following immune reconstitution or immunomodulatory treatment: should we manage it any differently?

(2014) Anthony P. Weetman   CLINICAL ENDOCRINOLOGY

Mode of action and clinical studies with alemtuzumab

(2014) Joanne L. Jones et al.   EXPERIMENTAL NEUROLOGY

Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy

(2014) O. Tuohy et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Disease modifying therapies in multiple sclerosis: Could a baseline thyroid check-up drive the therapeutic choice between interferon-β and glatiramer acetate?

(2014) Mario Rotondi et al.   Multiple Sclerosis Journal

Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study

(2014) Giovanni Frisullo et al.   Multiple Sclerosis Journal

Autoimmune thyroid disease following alemtuzumab therapy and hematopoietic cell transplantation in pediatric patients with sickle cell disease

(2014) Kristen M. Williams et al.   PEDIATRIC BLOOD & CANCER

Role of genetic and non-genetic factors in the etiology of Graves’ disease

(2014) M. Marinò et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

Autoimmune Thyroid Disease in the Use of Alemtuzumab for Multiple Sclerosis: A Review

(2013) Algenes Aranha et al.   Endocrine Practice

Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients With Relapsing-Remitting Multiple Sclerosis

(2013) Gilbert H. Daniels et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Reprogramming the immune repertoire with alemtuzumab in MS

(2013) Heinz Wiendl et al.   Nature Reviews Neurology

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

Alemtuzumab more effective than interferon  -1a at 5-year follow-up of CAMMS223 Clinical Trial

(2012) A. J. Coles et al.   NEUROLOGY

Human Peripheral Blood Mononuclear Cells Exhibit Heterogeneous CD52 Expression Levels and Show Differential Sensitivity to Alemtuzumab Mediated Cytolysis

(2012) Sambasiva P. Rao et al.   PLoS One

The incidence and prevalence of fibromyalgia are higher in multiple sclerosis than the general population: A population-based study

(2012) Ruth Ann Marrie et al.   Multiple Sclerosis and Related Disorders

The Chemokine System as a Therapeutic Target in Autoimmune Thyroid Diseases: A Focus on the Interferon-γ Inducible Chemokines and their Receptor

(2011) Mario Rotondi et al.   CURRENT PHARMACEUTICAL DESIGN

Interferon-β but not Glatiramer acetate stimulates CXCL10 secretion in primary cultures of thyrocytes: A clue for understanding the different risks of thyroid dysfunctions in patients with multiple sclerosis treated with either of the two drugs

(2011) Mario Rotondi et al.   JOURNAL OF NEUROIMMUNOLOGY

T cells in multiple sclerosis and experimental autoimmune encephalomyelitis

(2010) J. M. Fletcher et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Diseases associated with thyroid autoimmunity: explanations for the expanding spectrum

(2010) A. P. Weetman   CLINICAL ENDOCRINOLOGY

A Novel Strategy To Reduce the Immunogenicity of Biological Therapies

(2010) J. Somerfield et al.   JOURNAL OF IMMUNOLOGY

Immune reconstitution syndrome and the thyroid

(2009) Anthony Weetman   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: Twelve-year outcomes

(2008) Alice R. Lorenzi et al.   ARTHRITIS AND RHEUMATISM

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

(2008) Daniel D Mikol et al.   LANCET NEUROLOGY

Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis

(2008)   NEW ENGLAND JOURNAL OF MEDICINE